ORPH - CytRx announces Orphazyme's U.S. expansion ahead of potential regulatory approval of Arimoclomol

CytRx (CYTR) has announced that Orphazyme A/S (ORPH) announces the expansion of its U.S. presence and workforce ahead of potential Food and Drug Administration approval of arimoclomol for the treatment of Niemann-Pick disease Type C. CytRx has an agreement with Orphazyme that can yield potential milestone payments and future royalties paid on sales of arimoclomol. Orphazyme’s U.S. team, which is focused on regulatory review efforts and a first potential commercial launch in 2021, includes legal, commercial, finance, advocacy relations, and regulatory and medical affairs functions. Source: Press Release

For further details see:

CytRx announces Orphazyme’s U.S. expansion ahead of potential regulatory approval of Arimoclomol